Evidence map›Paper›PMID 35187191›Full record

ArticleOpen forum infectious diseases2022

Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment.

Christopher Brokus, Sarah Kattakuzhy, Britt Gayle, Shivakumar Narayanan, Ashley Davis, Amelia Cover, Rahwa Eyasu, Emade Ebah, Onyinyechi Ogbumbadiugha-Weekes, Jennifer Hoffmann and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 2 institutions in 1 country.

Christopher BrokusDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Sarah KattakuzhyDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Britt GayleDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Shivakumar NarayananDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Ashley DavisDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Amelia CoverDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Rahwa EyasuDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Emade EbahDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Onyinyechi Ogbumbadiugha-WeekesDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Jennifer HoffmannDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Rachel SilkDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Jasmine StevensDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Julia MountDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Catherine GannonDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Laura NussdorfDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Poonam MathurDivision of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-1346-9388
Phyllis BijoleHIPS, Washington, District of Columbia, USA.
Miriam JonesHIPS, Washington, District of Columbia, USA.
Randy KierHIPS, Washington, District of Columbia, USA.
David SternbergHIPS, Washington, District of Columbia, USA.
Aaron GreenblattDivision of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Eric WeintraubDivision of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Henry MasurDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Shyamasundaran KottililDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
Elana RosenthalDC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.
University of Maryland, Baltimore · USAIDS United · US

Funding

Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugsR01DA043396 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI KOTTILIL, SHYAMASUNDARAN · 2017 to 2021
$2.3M
Pittsburgh HIV Mentored Training for Investigation of Co-morbidities and Cure (HIV MeTrICC)K12HL143886 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MELLORS, JOHN W, MORRIS, ALISON · 2018 to 2022
$1.7M
Ghana-SPARCO: Ghana Sickle Pan-African Research ConsortiumU01HL157004 · NHLBI · KWAME NKRUMAH UNIVERSITY/SCIENCE/TECH · PI OFORI-ACQUAH, SOLOMON FIIFI, SARFO, FRED STEPHEN · 2021 to 2025
$1.4M
CLC NIH HHS HHSN269201400012CNHLBI NIH HHS K12 HL143886NHLBI NIH HHS U01 HL157004NIDA NIH HHS R01 DA043396
6 · The paper itself

Abstract

backgroundDaily oral preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevents human immunodeficiency (HIV) among people who inject drugs (PWID). Despite rising HIV incidence and injection drug use (IDU), PrEP use remains low and there is limited research about uptake, adherence, and retention among PWID.

methodsThe ANCHOR investigation evaluated a community-based care model collocating hepatitis C virus (HCV) treatment, medication for opioid use disorder (OUD), and PrEP in individuals in Washington, DC, and Baltimore, Maryland. PrEP counseling was conducted from HCV treatment day 0 until week 24. Subjects could start any time during this window, were followed for 48 weeks, and were assessed for adherence by self-report and dried blood spot TDF analysis.

resultsOne hundred ninety-eight participants were enrolled, of whom 185 (93%) were HIV negative. Twenty-nine individuals (15.7% of HIV-negative cohort) initiated PrEP. One hundred sixteen participants (62.7%) met 2014 Centers for Disease Control and Prevention (CDC) PrEP criteria due to IDU (82 [44.3%]), sex (9 [4.9%]), or both practices (25 [13.5%]). Providers recommended PrEP to 94 individuals (50.8%), and recommendation was associated with PrEP uptake. Median treatment duration was 104 days (interquartile range, 28-276 days), with 8 participants retained through week 48. Adherence was variable over time by self-report and declined by TDF analysis. No HIV seroconversions occurred.

conclusionsThis cohort of people with HCV and OUD experienced low uptake of PrEP despite the majority meeting CDC criteria. High rates of disruption and discontinuation, compounded by variable adherence, made TDF/FTC a suboptimal prevention strategy. Emerging modalities like long-acting formulations may address these barriers, but PWID have been excluded from their development to date.

Indexed as

HCVopioid use disorderOUDPrEPPWID

Identifiers

PMID35187191
PMCPMC8849288
OpenAlexW4200608092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.